Eterna Regeneratives is a UK biotechnology spin-out from King's College London, founded in 2024 by Khaled Eissa and Sherif Elsharkawy. Backed by Hoxton Ventures and The Venture Collective, Eterna is building a biomaterials platform for mineralisation and tissue regeneration, with initial applications in enamel repair and bone. Their patented platform uses keratin, derived from sheep's wool, to guide new mineral growth at the site of damage, working with the body's own chemistry beyond just protection. The company has now grown into a new lab space in Canary Wharf, where they are focused on commercialising their product, building their IP pipeline, and partnering with healthcare companies to bring their product to the mass market.
Eterna Regeneratives: Venture Capital Funding History
Eterna Regeneratives
Eterna Regeneratives
- Life Sciences
- London, United Kingdom
- eternaregeneratives.co
- Update Information
More venture news
- 26 Oct 2026

adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences - 26 Oct 2026

imphatecimphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions
SeedLife Sciences - 15 Oct 2026

OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences
